Literature DB >> 34014434

Low prevalence of tissue detection of cefepime and daptomycin used as empirical treatment during revision for periprosthetic joint infections: results of a prospective multicenter study.

O Robineau1,2, E Talagrand-Reboulh3, B Brunschweiler4, F Jehl3, E Beltrand5, F Rousseau6, N Blondiaux7, A Grillon3, C Joseph8, P Lambotte9, P Boyer3, Eric Senneville10,11.   

Abstract

Data demonstrating that antibiotics administered intraoperatively in patients with surgical revision for periprosthetic joint infection achieve concentrations exceeding minimal inhibitory concentrations of the identified bacteria at the surgical site when the new implant is inserted are lacking. We prospectively included patients with periprosthetic joint infection operated with one- or two-stage replacement during which cefepime (2g)-daptomycin (10mg/kg) combination was administered intravenously as intraoperative empirical antibiotic treatment. Three biopsies (two bones and one synovial membrane) were taken from each patient just before the insertion of the new implant. Eighteen adults of median age 68 years were included. Knee was involved in 10 patients (55.6%) and surgery consisted in one-/two-stage replacement in 11/7 patients. A tourniquet was used during the intervention in the 10 patients with knee prosthesis. Among 54 tissue samples, cefepime and daptomycin were detected respectively in 35 (64.8%) and 21 (38.9%) cases (P=0.01). A total of 17 bacteria dominated by staphylococci (n=14) were identified in 10 patients; tissue inhibitory quotient calculated in 51 samples was >1 in 22 cases (43.1%) for cefepime and in 16 cases (31.4%) for daptomycin. The proportion of tissue samples with detectable antibiotic was significantly higher in hip versus knee prosthesis (P=0.03). The present study suggests that intraoperative empirical administration of cefepime-daptomycin combination during septic prosthetic joint replacement results in a high proportion of tissue samples in which at least one of the two antibiotics was not detected or at a low concentration despite satisfactory concomitant blood serum concentrations.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cefepime; Daptomycin; Dosage; Empirical antibiotic therapy; Inhibitory quotient; Periprosthetic joint infection; Tourniquet

Mesh:

Substances:

Year:  2021        PMID: 34014434     DOI: 10.1007/s10096-021-04277-4

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  34 in total

1.  Successful single-dose prophylaxis of Staphylococcus aureus foreign body infections in guinea pigs by fleroxacin.

Authors:  N Bouchenaki; P E Vaudaux; E Huggler; F A Waldvogel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

2.  Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America.

Authors:  Douglas R Osmon; Elie F Berbari; Anthony R Berendt; Daniel Lew; Werner Zimmerli; James M Steckelberg; Nalini Rao; Arlen Hanssen; Walter R Wilson
Journal:  Clin Infect Dis       Date:  2012-12-06       Impact factor: 9.079

3.  Probabilistic chemotherapy in knee and hip replacement infection: the place of linezolid.

Authors:  Luc Deroche; Chloé Plouzeau; Pascale Bémer; Didier Tandé; Anne Sophie Valentin; Anne Jolivet-Gougeon; Carole Lemarié; Laurent Bret; Marie Kempf; Geneviève Héry-Arnaud; Stéphane Corvec; Christophe Burucoa; Cédric Arvieux; Louis Bernard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-06-15       Impact factor: 3.267

4.  Pathogenesis of foreign body infection: description and characteristics of an animal model.

Authors:  W Zimmerli; F A Waldvogel; P Vaudaux; U E Nydegger
Journal:  J Infect Dis       Date:  1982-10       Impact factor: 5.226

Review 5.  Perioperative antibiotic prophylaxis of wound and foreign body infections: microbial factors affecting efficacy.

Authors:  F A Waldvogel; P E Vaudaux; D Pittet; P D Lew
Journal:  Rev Infect Dis       Date:  1991 Sep-Oct

6.  Short-term administration of rifampin in the prevention or eradication of infection due to foreign bodies.

Authors:  K Tshefu; W Zimmerli; F A Waldvogel
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

7.  A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention.

Authors:  Jaime Lora-Tamayo; Oscar Murillo; José Antonio Iribarren; Alex Soriano; Mar Sánchez-Somolinos; Josu Miren Baraia-Etxaburu; Alicia Rico; Julián Palomino; Dolors Rodríguez-Pardo; Juan Pablo Horcajada; Natividad Benito; Alberto Bahamonde; Ana Granados; María Dolores del Toro; Javier Cobo; Melchor Riera; Antonio Ramos; Alfredo Jover-Sáenz; Javier Ariza
Journal:  Clin Infect Dis       Date:  2012-08-31       Impact factor: 9.079

8.  Guiding empirical antibiotic therapy in orthopaedics: The microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention.

Authors:  E Moran; S Masters; A R Berendt; P McLardy-Smith; I Byren; B L Atkins
Journal:  J Infect       Date:  2007-03-06       Impact factor: 6.072

Review 9.  Preoperative Aspiration Culture (PAC) for the Diagnosis of Infection in a Prosthetic Knee Joint.

Authors:  E Carlos Rodriguez-Merchan
Journal:  Arch Bone Jt Surg       Date:  2018-09

10.  Italian guidelines for the diagnosis and infectious disease management of osteomyelitis and prosthetic joint infections in adults.

Authors:  S Esposito; S Leone; M Bassetti; S Borrè; F Leoncini; E Meani; M Venditti; F Mazzotta
Journal:  Infection       Date:  2009-11-10       Impact factor: 7.455

View more
  1 in total

Review 1.  Clinical Pharmacokinetics and Pharmacodynamics of Cefepime.

Authors:  Gwendolyn M Pais; Jack Chang; Erin F Barreto; Gideon Stitt; Kevin J Downes; Mohammad H Alshaer; Emily Lesnicki; Vaidehi Panchal; Maria Bruzzone; Argyle V Bumanglag; Sara N Burke; Marc H Scheetz
Journal:  Clin Pharmacokinet       Date:  2022-06-29       Impact factor: 5.577

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.